ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2830

Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study

Zachary Wallace1, Tyler Harkness 1, Xiaoqing Fu 1, John Stone 2, Hyon K. Choi 3 and Rochelle Walensky 1, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: glucocorticoids and treatment, infusions, prior authorization

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T111: Measures of Healthcare Quality II: Quality Improvement in Rheumatology – Still Getting Better (2828–2833)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Prior authorizations (PA) are commonly required by health payers as cost-containment strategies for expensive medications, including infused biologics. In rheumatology, these medications are frequently prescribed to treat rare conditions that can be organ- or life-threatening and for which few or no medications have regulatory approval because of their relative scarcity. Infused medications often have neither generic substitutes nor oral or subcutaneous formulations and inevitably require advanced planning to administer. There are scarce data about the effect of PA requirements for infused medications on patient-oriented outcomes.

Methods: We included subjects for whom an infusible medication was prescribed in our academic rheumatology practice for a rheumatologic condition. The exposures of interest were a PA requirement and the PA outcome (approved vs. denied). The primary outcome was the difference in days from medication request to infusion. Secondary outcomes included time to PA approval, the proportion of denied PAs, and glucocorticoid exposure among those approved and denied following PA request.

Results: Of the 225 subjects (Table 1), 160 (71%) required a PA.  Of the PA-requiring cases, the conditions most often being treated were inflammatory arthritis (44, 28%) and vasculitis (37, 23%).  In 67 (42%) cases requiring a PA, the condition had no FDA-approved medication.  The PA request was initially denied in 33 (21%) subjects, 21 (64%) of whom had conditions with no FDA-approved medications (Table 2); twenty-seven (82%) of these denials were eventually approved.  Thus, 96% of all PAs were ultimately approved.  PAs were associated with a greater median number of days to infusion compared to cases in which no authorization was required (31 days [15, 60] vs 27 days [13, 41], p=0.045; Table 3).  Compared to those in whom no PA was required, subjects in whom a PA request was initially denied had substantially longer time to approval (22 days [15, 41] vs 0 days [0, 0]), P< 0.001) and infusion (50 days [31, 76] vs 27 days [13, 41], P< 0.001).  PA denials were associated with a 3.8-fold greater median prednisone-equivalent glucocorticoid exposure in the 3 months following the request than when a PA was not required (605mg [0, 1575] vs 160mg [0, 675], P=0.01).

Conclusion: PA requirements for infusible medications are associated with delays in treatment.  There is a striking three-week delay to approval and one-month delay to treatment among those whose PAs are initially denied.  PA denials are further associated with excess glucocorticoid exposure.  Thus, PAs constitute a barrier to the introduction of effective treatment in an expeditious manner.  Because the great majority of PA requests are ultimately approved, the value of PA requirements and their impact on patient safety should be re-evaluated.

Baseline Cohort Demographics

Characteristics of Denied Prior Authorizations

Patient-Oriented Outcomes Following Prior Authorization -PA- Request Submission According to Prior Authorization Requirement


Disclosure: Z. Wallace, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, 2, Rheumatology Research Foundation, 2; T. Harkness, None; X. Fu, None; J. Stone, Genentech, 2, 5, Roche, 2, 5, Xencor, 2, 5; H. Choi, AstraZeneca, 2, GSK, 5, Horizon, 5, Selecta, 5, Takeda, 5; R. Walensky, None.

To cite this abstract in AMA style:

Wallace Z, Harkness T, Fu X, Stone J, Choi H, Walensky R. Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/treatment-delays-associated-with-prior-authorization-for-infusible-medications-a-cohort-study/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-delays-associated-with-prior-authorization-for-infusible-medications-a-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.